Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016

Description: Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H2 2016, provides an overview of the Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline landscape.

Cushing disease is a condition in which the pituitary gland releases too much adrenocorticotropic hormone (ACTH). Symptoms include acne or skin infections, backache, mental changes, such as depression, anxiety, or changes in behavior. Treatment includes surgery and radiation therapy.

Report Highlights:

The Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion.
(Metabolic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction

Pituitary ACTH Hypersecretion (Cushing Disease) Overview

Therapeutics Development

Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Overview

Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis

Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Development by Companies

Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Investigation by Universities/Institutes

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Development by Companies

Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Investigation by Universities/Institutes

Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development

Amryt Pharma plc

Corcept Therapeutics Inc

Cyclacel Pharmaceuticals Inc

ElexoPharm GmbH

Ipsen SA

Millendo Therapeutics Inc

Novartis AG
Orphagen Pharmaceuticals Inc
Pfizer Inc
Reset Therapeutics Inc
Strongbridge Biopharma plc
XOMA Corp

Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

ATR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

BIM-23B065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

ketoconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

levoketoconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mifepristone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPP-482 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osilodrostat phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects

Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products

Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones

Featured News & Press Releases

Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder

Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo


Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014

Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014

Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting

Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial

Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing's Syndrome

Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing's Syndrome

Appendix
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2016

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Amryt Pharma plc, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Corcept Therapeutics Inc, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by ElexoPharm GmbH, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Ipsen SA, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Millendo Therapeutics Inc, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Novartis AG, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Pfizer Inc, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Reset Therapeutics Inc, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H2 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by XOMA Corp, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H2 2016
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H2 2016

List of Figures
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2016
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/4015273/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016
Web Address: http://www.researchandmarkets.com/reports/4015273/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprise Wide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World